Metolazone and spironolactone in cirrhosis and the nephrotic syndrome.
Eighteen patients with hepatic cirrhosis or nephrotic syndrome and having edema and/or ascites were treated during successive periods with metolazone 5 to 40 mg/day, spironolactone 100 mg/day, and with both diuretics concurrently. Metolazone alone produced a marked diuresis, natriuresis, and weight loss in 8 patients. Spironolactone alone had little effect, but the addition of metolazone renewed diuresis and natriuresis and resulted in additional substantial weight losses in all patients responsive to metolazone alone. Concurrent spironolactone and metolazone also induced moderate diuretic effects in some patients who failed to respond to either drug alone. The drugs were well tolerated; the administration of spironolactone with metolazone prevented decreases in serum potassium, which had occurred during treatment with metolazone alone.
D000328:Adult; D000368:Aged; D001772:Blood Cell Count; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002712:Chlorides / Q000652:urine; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004231:Diuresis / Q000187:drug effects; D004232:Diuretics / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008788:Metolazone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011188:Potassium / Q000097:blood / Q000652:urine; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D001786:Blood Glucose; D002712:Chlorides; D004232:Diuretics; D013148:Spironolactone; D012964:Sodium; D003404:Creatinine; D011188:Potassium; D008788:Metolazone